Efonidipine

Efonidipine

SCHEMBL29410289

CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)[C@@H](c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 1.00
CACNA1C Q13936 10/20 0.59
CYP1A2 P05177 4/20 0.59
CYP3A4 P08684 4/20 0.59
CYP2D6 P10635 4/20 0.59
CYP2C9 P11712 4/20 0.59
CYP2C19 P33261 4/20 0.59
LMNA P02545 3/20 0.59
MAPT P10636 3/20 0.59
TDP1 Q9NUW8 3/20 0.59
TSHR P16473 3/20 0.59
ADORA3 P0DMS8 3/20 0.59
ADRA2A P08913 2/20 0.59
TBXA2R P21731 2/20 0.59
NPC1 O15118 1/20 0.59
ABCC4 O15439 1/20 0.59
ABCB11 O95342 1/20 0.59
PGR P06401 1/20 0.59
CHRM2 P08172 1/20 0.59
HTR1A P08908 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Efonidipine SCHEMBL49637 1.00 ABCB1 (1.00) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL29379054 1.00 ABCB1 (1.00) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL49638 1.00 ABCB1 (1.00) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL349046 0.99 ABCB1 (0.99) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL332377 0.99 ABCB1 (0.99) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL678571 0.99 ABCB1 (0.97) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL28844127 0.99 ABCB1 (0.97) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL27650540 0.98 ABCB1 (0.96) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL909287 0.97 ABCB1 (0.95) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6
Efonidipine SCHEMBL909286 0.97 ABCB1 (0.95) ABCB1CACNA1CCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615010-B1 METHODS FOR TREATING DRAVET SYNDROME CAVION INC (US) 2024-08-21 EP disclosed
CN-110770221-B Methods for improving memory and cognition and for treating memory and cognition disorders 卡维昂公司 2023-09-08 CN disclosed
EP-3364993-B1 METHODS FOR TREATING ANGELMAN SYNDROME CAVION INC (US) 2022-11-09 EP disclosed
US-11324733-B2 Methods for improving memory and cognition and for treating memory and cognitive disorders CAVION, INC. (US) 2022-05-10 US disclosed
US-11273218-B2 Methods for treating Angelman syndrome and related disorders CAVION, INC. (US) 2022-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11273218-B2 Methods for treating Angelman syndrome and related disorders CACNA1G, CACNA1I, CACNA1H ABCB1 1948/4885CACNA1C 16/4885CYP1A2 4539/4885
US-11324733-B2 Methods for improving memory and cognition and for treating memory and cognitive disorders CACNA1G, CACNA1I, CACNA1H ABCB1 3075/4885CACNA1C 8/4885CYP1A2 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.